In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38560908.
- Also identified by DOI 10.7326/J24-0016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ray KK, Nicholls SJ, Li N, et al; CLEAR OUTCOMES Committees and Investigators. <b>Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.</b> Lancet Diabetes Endocrinol. 2024;12:19-28. 38061370.
Medical subject headings
- Diabetes Mellitus
- Hydroxymethylglutaryl-CoA Reductase Inhibitors